Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor for diabetes and cardiometabolic diseases.
Stocks · News reference
8-K filing — Kura Oncology, Inc. (KURA)
Filed: 2026-09-09 AccNo: 0001193125-26-385881 Size: 142 KB Item 8.01: Other Events
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kura Oncology Announces Launch Of Caspian Therapeutics With $50M Financing Led By BVF Partners, With Eli Lilly Participating, To Advance Menin Inhibitor KO-7246 In Diabetes; Retains About Half Ownership
Kura Oncology Appoints Jennifer Fulk As CFO, Effective September 8
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE